Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma.
J Cancer Res Clin Oncol
; 150(7): 347, 2024 Jul 11.
Article
en En
| MEDLINE
| ID: mdl-38990367
ABSTRACT
BACKGROUND:
Therapeutic approach used for pancreatic ductal adenocarcinoma is usually translated also for the rarer acinar counterpart, which shows a different mutational landscape nevertheless. While dMMR/MSI-H status is rare in the ductal histotype, it appears to be more prevalent in pancreatic acinar cell carcinoma (PACC). CASE PRESENTATION We report the case of a patient with locally advanced MSI-H PACC in whom the treatment with the anti-PD-1 pembrolizumab, administered as third line, made possible surgical resection, achieving even an exceptional pathological complete response.CONCLUSIONS:
Treatment of PACC should be tailored based on the peculiar molecular features that distinguish PACC from ductal adenocarcinoma. Evaluation of potentially therapeutically targetable alterations should be mandatory in case of PACC diagnosis.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Carcinoma de Células Acinares
/
Anticuerpos Monoclonales Humanizados
Límite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Cancer Res Clin Oncol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia